从抑制胆固醇吸收谈如何减少血液中胆固醇PPT.ppt

;Plasma Cholesterol and Coronary Heart Disease (CHD);Mean LDL-Cholesterol;Elbow Tuberous Xanthoma (15Ys Chinese Girl, FH?); ;Monogenic Hypercholesterolemia;Targets of Cholesterol Lowering Drugs;Targets of Cholesterol Lowering Drugs (continue);Why as low as 70?;Glucuronidation;Intestinal Sterol Absorption and Excretion; ;Switching to Ezetimibe/Simvastatin vs Doubling Statin Doses in Patients with CHD and/or Diabetes;Switching to Ezetimibe/Simvastatin More Effective Than Doubling Statin Dose;Switching to Ezetimibe/Simvastatin Superior to Doubling Statin Dose Across Most Lipid Subfractions;The Best Option?;Clinical Trial: ENHANCE Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression; ; ;B-mode ultrasound technique;TRIAL;TRIAL;TRIAL; ; ;Effects of Ezetimibe on Sitosterolemia;Cholesterol;Cholesterol;Major Features of Sitosterolemia;Ezetimibe Reduces Blood Sitosterol in Sitosterolemic Humans;Campesterol;Genetic Ablation of NPC1L1 Prevents Sitosterolemia in Mice Lacking ABCG5/G8;Other Potential Beneficial Effects of Ezetimibe; WT-T 3.4±0.4a 2.3±0.4a 12.3±0.7a 241.8±29.1b L1KO-V 4.1±0.3a 3.6±0.2a 18.8±0.5a 48.0±7.5a L1KO-T 3.0±0.3a 2.9±0.3a 19.1±0.5a 110.8±27.3a;Other Potential Beneficial Effects of Ezetimibe;NPC1L1 deficiency prevents a high fat diet-induced obesity in pure C57BL/6 mice;NPC1L1 deficiency prevents a high fat diet-induced obesity in pure C57BL/6 mice;Is Ezetimibe a Solution of Modern Diseases (High Fat Diet-Induced Obesity, Insulin Resistance, Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Diseases)?;Acknowledgments;;Switching to Ezetimibe/Simvastatin Superior to Doubling Statin Dose